AVTX (Avalo Therapeutics) Cyclically Adjusted PS Ratio: (As of Jul. 09, 2026)


AVTX Avalo Therapeutics Inc AVTX
23 GF Score
Price $19.22
GF Value $0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Avalo Therapeutics  (NAS:AVTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Avalo Therapeutics Cyclically Adjusted PS Ratio Related Terms


Avalo Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Avalo Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalo Therapeutics Cyclically Adjusted PS Ratio Chart

Avalo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.01 0.01 0.02

Avalo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.02 0.00

AVTX vs SANA, ANRO, REPL: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalo Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PS Ratio falls into.


AVTX
23GF Score
Avalo Therapeutics Inc AVTX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalo Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Avalo Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Avalo Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Avalo Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 216.667 241.018 296.850
201609 107.000 241.428 146.349
201612 60.333 241.432 82.519
201703 96.000 243.801 130.026
201706 31.600 244.955 42.599
201709 2,086.500 246.819 2,791.476
201712 203.091 246.524 272.036
201803 407.545 249.554 539.269
201806 435.000 251.989 570.035
201809 339.583 252.439 444.205
201812 -451.000 251.233 -592.781
201903 171.733 254.202 223.084
201906 92.800 256.143 119.635
201909 146.733 256.759 188.711
201912 38.733 256.974 49.772
202003 144.947 258.115 185.434
202006 60.818 257.797 77.902
202009 42.731 260.280 54.212
202012 57.577 260.474 72.993
202103 15.258 264.877 19.022
202106 101.667 271.696 123.564
202109 38.571 274.310 46.432
202112 4.761 278.802 5.639
202203 30.077 287.504 34.545
202206 26.487 296.311 29.517
202209 383.308 296.808 426.448
202212 22.974 296.797 25.561
202303 9.694 301.836 10.605
202306 11.086 305.109 11.998
202309 1.210 307.789 1.298
202312 0.712 306.746 0.766
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.023 315.301 0.024
202412 0.018 315.605 0.019
202503 0.000 319.799 0.000
202506 0.000 322.561 0.000
202509 0.000 324.800 0.000
202512 0.003 324.054 0.003
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Avalo Therapeutics (AVTX) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of $19.22 is trading 63950% above its estimated GF Value™ of $0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for AVTX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $0.03 vs. price of $19.22 (63950% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the AVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Avalo Therapeutics Business Description

Other Exchanges C6K0:Germany
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
23GF Score

Get the complete analysis for AVTX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.22
Price
$0.03
GF Value